Polyphor

About Polyphor

Polyphor is a biopharmaceutical company focused on developing innovative therapies for severe diseases, particularly targeting Gram-negative resistant pathogens and metastatic cancer. The company operates in the healthcare and pharmaceutical markets, serving patients with unmet medical needs and collaborating with other pharmaceutical companies. Polyphor's business model revolves around drug discovery and development, leveraging its proprietary OMPTA and macrocycle platforms to create novel antibiotics and oncology treatments. Revenue is generated through licensing agreements, collaborations, and the commercialization of its drug candidates. Key products in its pipeline include Balixafortide (POL6326), a CXCR4 inhibitor for metastatic breast cancer, and POL7306, a preclinical compound targeting Gram-negative pathogens. The company also has a cystic fibrosis therapy, POL6014, outlicensed to Santhera Pharmaceuticals.